Sichuan Amidala Technology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Sichuan Amidala Technology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include LEIDIAK. The owner is based in Chengdu City, Sichuan.

No.299 Yinxing Avenue, Jinjiang Dist.

1512, 15/F, Building 2

Chengdu City, Sichuan 610066 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

LEIDIAK
LEIDIAK
Registered 2024

Trademark Classifications

Sichuan Amidala Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does Sichuan Amidala Technology Co., Ltd. have?

Sichuan Amidala Technology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Sichuan Amidala Technology Co., Ltd. file in?

Sichuan Amidala Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 9 (Computers & Electronics). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.

What are Sichuan Amidala Technology Co., Ltd.'s most well-known trademarks?

Sichuan Amidala Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as LEIDIAK. These are among 1 currently registered trademark in the portfolio.

What is Sichuan Amidala Technology Co., Ltd.'s trademark registration success rate?

Sichuan Amidala Technology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.